Zobrazeno 1 - 10
of 2 434
pro vyhledávání: '"second line treatment"'
Autor:
Choong-kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee
Publikováno v:
Liver Cancer, Pp 1-15 (2024)
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients w
Externí odkaz:
https://doaj.org/article/48cd992dee674cbb8551afa29b350663
Publikováno v:
AIDS Research and Therapy, Vol 21, Iss 1, Pp 1-7 (2024)
Abstract Background Effective management of antiretroviral therapy (ART) is crucial in combating the global HIV pandemic. This study, the first of its kind in Yemen, investigates the rate and determinants of switching from first-line to second-line A
Externí odkaz:
https://doaj.org/article/1f052fad3e2644ddab697b0b279492b4
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 771-780 (2024)
Weixin Bei,1,2,* Shuhui Dong,1,2,* Guoying Liu,1,3,4,* Lanfeng Lin,2,5,* Yaofei Jiang,1,2 Nian Lu,1,2 Wangzhong Li,1,2 Hu Liang,1,2 Yanqun Xiang,1,2 Weixiong Xia1,2 1Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cance
Externí odkaz:
https://doaj.org/article/0ad5a810d2854e8d87fe1cd48e5677d5
Autor:
Pinelopi Arvaniti, Ignasi Olivas, Sergio Rodriguez-Tajes, George N. Dalekos, Maria-Carlota Londoño
Publikováno v:
Exploration of Digestive Diseases, Vol 3, Iss 2, Pp 92-106 (2024)
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown aetiology that can lead to end stage liver disease if left without treatment. Corticosteroids with or without azathioprine (AZA) are considered the recommended standard first-line treat
Externí odkaz:
https://doaj.org/article/f4e2757a52954dcdb40b0c6bfabe588e
Autor:
Kanwal Asghar, Maryam Zafar, Eva Holland, Ali Bin Abduljabbar, Sara A. Albagoush, Noureen Asghar, Akshat Sood, Jalal M. Dufani, Joseph Thirumalaredy, Bradley DeVrieze, Abubakar Tauseef, Muhammad Husnain
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionInconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell
Externí odkaz:
https://doaj.org/article/5ca47676a1184f45ba516d15dd1a524a
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 4, Iss , Pp 100055- (2024)
Background: Biliary cancers are aggressive carcinomas frequently diagnosed at an advanced stage. Palliative combination systemic therapy provides survival benefits in the first-line setting of advanced and metastatic disease. FOLFOX chemotherapy is o
Externí odkaz:
https://doaj.org/article/98f42e2ff5454aaf9317f9410a4b207e
Publikováno v:
Pharmacological Research, Vol 202, Iss , Pp 107108- (2024)
Background: Optimizing second-line biologic therapies for adult ulcerative colitis (UC) post first-line failure is essential. Objective: Compare second-line biologic therapy efficacy in adult UC patients with prior treatment failure. Methods: A compr
Externí odkaz:
https://doaj.org/article/c8987ad75fdf45709cdc94c6f7d3db70
Publikováno v:
Liver Cancer, Pp 1-10 (2023)
Background: Immune checkpoint inhibitor (ICI)-based therapy such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab became mainstream first-line systemic treatment in advanced hepatocellular carcinoma (HCC) patients since remarkably sup
Externí odkaz:
https://doaj.org/article/efe0942ec76744adaa84dc30f6067185
Autor:
Yosuke Murakami, Yosuke Kawashima, Shinji Chiba, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Publikováno v:
Cancer Reports, Vol 7, Iss 2, Pp n/a-n/a (2024)
Abstract Background Anaplastic lymphoma kinase (ALK)‐positive lung cancer has a better long‐term prognosis with ALK‐inhibitor than other lung cancers. However, resistance to ALK‐inhibitors and the control of metastases in the central nervous
Externí odkaz:
https://doaj.org/article/6a69036d500340d1912700c168116d18
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chromophobe renal cell carcinoma (ChRCC) is a rare pathological type of renal cell carcinoma (RCC). Related systematic studies involving large numbers of patients are lacking, and more importantly, there is currently no international consensus on pos
Externí odkaz:
https://doaj.org/article/2ecd8210aee54dd780ffb5fae81bf24c